Geode Capital Management
SLN

Geode Capital Management’s Silence Therapeutics SLN Stock Holding History

Geode Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$156K Hold
29,538
– – ﹤0.01% 4003
2025
Q4 		$180K Hold
29,538
– – ﹤0.01% 3942
2025
Q3 		$153K Hold
29,538
– – ﹤0.01% 4013
2025
Q2 		$171K Buy
29,538
+121
+0.4% +$519 ﹤0.01% 3923
2025
Q1 		$83K Hold
29,417
– – ﹤0.01% 4081
2024
Q4 		$202K Hold
29,417
– – ﹤0.01% 3905
2024
Q3 		$535K Hold
29,417
– – ﹤0.01% 3562
2024
Q2 		$559K Buy
29,417
+6,990
+31% +$149K ﹤0.01% 3528
2024
Q1 		$484K Hold
22,427
– – ﹤0.01% 3631
2023
Q4 		$390K Buy
22,427
+1,103
+5% +$12.4K ﹤0.01% 3707
2023
Q3 		$210K Buy
21,324
+4,117
+24% +$30.4K ﹤0.01% 3963
2023
Q2 		$94.6K Buy
17,207
+2,520
+17% +$15.2K ﹤0.01% 4352
2023
Q1 		$91.1K Buy
14,687
+1,510
+11% +$17.8K ﹤0.01% 4376
2022
Q4 		$200K Hold
13,177
– – ﹤0.01% 4104
2022
Q3 		$130K Buy
+13,177
New +$139K ﹤0.01% 4438

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Geode Capital Management's SLN Position: Q1 2026 in Review

Geode Capital Management held its Silence Therapeutics (SLN) position steady in Q1 2026 at 29,538 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

Geode Capital Management first reported a position in SLN in Q3 2022 and has held it in 15 quarters since. The position peaked at $559K in Q2 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Geode Capital Management held 29,538 shares of Silence Therapeutics worth $156K as of Q1 2026.
  • Geode Capital Management left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4003 holding.
  • Geode Capital Management first reported a position in Silence Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Geode Capital Management's Silence Therapeutics position peaked at $559K in Q2 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.